Dengue: Status of current and under-development vaccines - PubMed (original) (raw)
Review
doi: 10.1002/rmv.2101. Epub 2020 Feb 26.
Affiliations
- PMID: 32101634
- DOI: 10.1002/rmv.2101
Free article
Review
Dengue: Status of current and under-development vaccines
Marianna Redoni et al. Rev Med Virol. 2020 Jul.
Free article
Abstract
Dengue is an emerging mosquito-borne viral infection with increasing reports of outbreaks. The clinical picture ranges from a benign febrile illness through to severe and potentially fatal manifestations. No specific anti-viral treatment exists, and therapy only consists of supportive care. During the last three decades, several attempts to develop an effective vaccine have been made. The first dengue vaccine to obtain licensure was Dengvaxia, which was authorized in 2015 and is currently available in over 20 countries. Its use has been approved with strict limitations regarding age and serostatus of the recipients, highlighting the necessity for a more safe and efficacious vaccine. At present several vaccine, candidates are undergoing clinical and pre-clinical trials. The most advanced candidates are TDV and TDV 003/005, two live-attenuated vaccines, but another 15 vaccines are under development, introducing novel immunization strategies to the traditional dengue vaccine scenario. This work reviews the current research status on dengue vaccines.
Keywords: dengue; vaccination; vaccine.
© 2020 John Wiley & Sons, Ltd.
Similar articles
- A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
Lee JS, Lourenço J, Gupta S, Farlow A. Lee JS, et al. Vaccine. 2018 Apr 19;36(17):2346-2355. doi: 10.1016/j.vaccine.2018.03.002. Epub 2018 Mar 21. Vaccine. 2018. PMID: 29573874 - Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.
Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon IK, Hombach J. Wichmann O, et al. Vaccine. 2017 Oct 9;35(42):5535-5542. doi: 10.1016/j.vaccine.2017.08.066. Vaccine. 2017. PMID: 28893477 Review. - Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL, Park J, López-Medina E, Capeding MR, Cadena Bonfanti AA, Montalbán MC, Ramírez I, Gonzales MLA, DiazGranados CA, Zambrano B, Dayan G, Savarino S, Chen Z, Wang H, Sun S, Bonaparte M, Rojas A, Ramírez JC, Verdan MA, Noriega F. Coronel-MartÍnez DL, et al. Lancet Infect Dis. 2021 Apr;21(4):517-528. doi: 10.1016/S1473-3099(20)30767-2. Epub 2020 Nov 16. Lancet Infect Dis. 2021. PMID: 33212067 Clinical Trial. - The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
Pitisuttithum P, Bouckenooghe A. Pitisuttithum P, et al. Expert Rev Vaccines. 2016 Jul;15(7):795-8. doi: 10.1080/14760584.2016.1189331. Expert Rev Vaccines. 2016. PMID: 27171845 No abstract available. - Dengue vaccines: challenges, development, current status and prospects.
Ghosh A, Dar L. Ghosh A, et al. Indian J Med Microbiol. 2015 Jan-Mar;33(1):3-15. doi: 10.4103/0255-0857.148369. Indian J Med Microbiol. 2015. PMID: 25559995 Review.
Cited by
- Trends and insights in dengue virus research globally: a bibliometric analysis (1995-2023).
Liu Y, Wang M, Yu N, Zhao W, Wang P, Zhang H, Sun W, Jin N, Lu H. Liu Y, et al. J Transl Med. 2024 Sep 3;22(1):818. doi: 10.1186/s12967-024-05561-5. J Transl Med. 2024. PMID: 39227968 Free PMC article. - Winged Threat on the Offensive: A Literature Review Due to the First Identification of Aedes japonicus in Poland.
Gierek M, Ochała-Gierek G, Woźnica AJ, Zaleśny G, Jarosz A, Niemiec P. Gierek M, et al. Viruses. 2024 Apr 29;16(5):703. doi: 10.3390/v16050703. Viruses. 2024. PMID: 38793584 Free PMC article. Review. - Immunological signatures unveiled by integrative systems vaccinology characterization of dengue vaccination trials and natural infection.
Plaça DR, Fonseca DLM, Marques AHC, Zaki Pour S, Usuda JN, Baiocchi GC, Prado CAS, Salgado RC, Filgueiras IS, Freire PP, Rocha V, Camara NOS, Catar R, Moll G, Jurisica I, Calich VLG, Giil LM, Rivino L, Ochs HD, Cabral-Miranda G, Schimke LF, Cabral-Marques O. Plaça DR, et al. Front Immunol. 2024 Feb 20;15:1282754. doi: 10.3389/fimmu.2024.1282754. eCollection 2024. Front Immunol. 2024. PMID: 38444851 Free PMC article. - Associations between Dengue Incidence, Ecological Factors, and Anthropogenic Factors in Singapore.
Tewari P, Guo P, Dickens B, Ma P, Bansal S, Lim JT. Tewari P, et al. Viruses. 2023 Sep 13;15(9):1917. doi: 10.3390/v15091917. Viruses. 2023. PMID: 37766323 Free PMC article. - Tracing down the Updates on Dengue Virus-Molecular Biology, Antivirals, and Vaccine Strategies.
Malik S, Ahsan O, Mumtaz H, Tahir Khan M, Sah R, Waheed Y. Malik S, et al. Vaccines (Basel). 2023 Aug 5;11(8):1328. doi: 10.3390/vaccines11081328. Vaccines (Basel). 2023. PMID: 37631896 Free PMC article. Review.
References
REFERENCES
- Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496:504-507.
- Na W, Yeom M, Choi IK, Yook H, Song D. Animal models for dengue vaccine development and testing. Clin Exp Vaccine Res. 2017;6:104-110.
- McArthur MA, Sztein MB, Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013;12:933-953.
- Tsai WY, Lin HE, Wang WK. Complexity of human antibody response to dengue virus: implication for vaccine development. Front Microbiol. 2017;8:1372.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical